Bupubili

Psidium cattleianum leaves and essential oils contain gallic acid, ellagic acid, quercetin derivatives, β-caryophyllene, and α-bisabolol that inhibit COX-2, 5-lipoxygenase, collagenase, and elastase through direct enzyme binding and copper chelation at active sites. In vitro assays demonstrate 90.37% collagenase inhibition and a leaf essential oil 5-lipoxygenase IC50 of 2.38 μL/mL, supporting its traditional application in gastrointestinal inflammation such as gastritis, though no human clinical trials have confirmed these effects.

Origin & History

Psidium cattleianum, commonly called strawberry guava, is native to eastern Brazil but has naturalized across tropical and subtropical Africa, including regions of Mozambique and Madagascar where it is locally known as Bupubili. It thrives in humid lowland forests and disturbed secondary vegetation, tolerating a range of soil types, which contributes to its invasive spread across African island ecosystems. Traditional cultivation is minimal; the plant largely grows wild and is harvested opportunistically from naturalized stands for food and medicinal use.

Historical & Cultural Context

In Mampa traditional medicine, Bupubili (Psidium cattleianum) is used as a remedy for gastritis, representing one of the few documented ethnomedicinal applications of this species on the African continent, where the plant arrived as an introduced species from its native Brazil. The Mampa people's use of leaf preparations for gastrointestinal complaints aligns with broader African ethnobotanical traditions of employing astringent, tannin-rich plant decoctions for digestive inflammation, ulceration, and diarrhea. In its native Brazil, closely related Psidium species have a long history of use in folk medicine for dysentery, diarrhea, and wounds, and it is plausible that traditional knowledge of the genus was transmitted or independently rediscovered following the plant's naturalization in Africa. Formal ethnobotanical documentation of Bupubili's preparation methods, dosage, and contraindications as practiced by the Mampa remains sparse in peer-reviewed literature, representing a significant research gap.

Health Benefits

- **Gastric Anti-Inflammatory Action**: Leaf extracts rich in ellagic acid and gallic acid suppress pro-inflammatory enzyme cascades including COX-2 (flower EO IC50 2.575 μL/mL) and 5-lipoxygenase (leaf EO IC50 2.38 μL/mL), providing a plausible molecular basis for the traditional Mampa use of Bupubili in gastritis management.
- **Antioxidant Protection**: Leaf dry extracts exhibit exceptionally high ABTS radical scavenging capacity at 535.62 ± 2.18 mg Trolox equivalents/g DE and DPPH activity of 0.54 ± 0.07 mg TE/g DE, indicating robust free-radical neutralization relevant to oxidative stress-driven gastric mucosal damage.
- **Extracellular Matrix Preservation**: Standardized leaf extracts inhibit collagenase by 90.37 ± 0.08% and elastase by 58.13 ± 1.08%, comparable to the reference compound EGCG, suggesting potential utility in protecting connective tissue integrity in inflamed mucosal or dermal environments.
- **Tyrosinase Inhibition and Skin Health**: Phenolic constituents, particularly gallic acid and quercetin glycosides, inhibit tyrosinase by 61.09 ± 1.17% via copper chelation at the enzyme's active site, indicating potential application in hyperpigmentation and melanogenesis-related skin conditions.
- **Potential Anticancer Activity**: Leaf essential oils induce cytotoxicity in MCF-7 human breast cancer cells with an IC50 of approximately 5.32 μg/mL, mediated through modulation of the p53/Bax/Bcl-2 apoptotic pathway, though this evidence is strictly preclinical and in vitro.
- **Nutritional Carotenoid and Anthocyanin Delivery**: Red strawberry guava fruits supply β-cryptoxanthin (44.8% of total carotenoids), cyanidin 3-glycoside as the dominant anthocyanin, fructose up to 22.83 g/100 g DM, and citric acid up to 135.35 mg/g DM, contributing antioxidant micronutrients relevant to mucosal health.
- **Anti-Infective and Antimicrobial Potential**: The sesquiterpene-rich essential oils, dominated by β-caryophyllene (up to 14.99%) and α-humulene (7.02%), exhibit bioactivities consistent with antimicrobial and anti-biofilm properties described for these compound classes, though pathogen-specific MIC data for Bupubili remain unpublished.

How It Works

Gallic acid and ellagic acid within leaf extracts chelate copper ions at the binuclear active site of tyrosinase, competitively blocking substrate oxidation and reducing melanin synthesis by 61.09% in vitro. β-Caryophyllene and α-bisabolol in leaf essential oils non-competitively inhibit 5-lipoxygenase (IC50 2.38 μL/mL) and COX-2 (IC50 2.575 μL/mL), attenuating leukotriene and prostaglandin biosynthesis central to the inflammatory cascade implicated in gastric mucosal injury. Quercetin derivatives and ellagitannins inhibit collagenase (90.37%) and elastase (58.13%) likely through direct binding to the enzyme's zinc-containing catalytic domain, preserving extracellular matrix integrity in inflamed tissues. Leaf EOs trigger intrinsic apoptosis in MCF-7 cells via upregulation of p53 and pro-apoptotic Bax with concurrent downregulation of anti-apoptotic Bcl-2, inducing mitochondrial membrane depolarization and caspase activation at an IC50 of approximately 5.32 μg/mL.

Scientific Research

All available evidence for Psidium cattleianum is limited to in vitro biochemical assays, cell-line cytotoxicity studies, and phytochemical characterization studies; no human clinical trials, randomized controlled trials, or animal intervention studies have been published specifically for the Bupubili application in gastritis. Enzyme inhibition studies (tyrosinase, collagenase, elastase, COX-2, 5-LOX) employed standardized spectrophotometric assays with quantified IC50 and percent inhibition values, representing internally consistent but non-translatable preclinical data. Phytochemical studies using LC-MS, GC-MS, supercritical fluid extraction, and hydrodistillation have robustly characterized the phenolic and volatile profiles of leaves, fruits, and flowers across multiple independent research groups, strengthening confidence in the compound inventory. The overall evidence base is best characterized as preliminary-to-preclinical, with an absence of pharmacokinetic, bioavailability, or dose-response data in living systems, substantially limiting clinical inference.

Clinical Summary

No human clinical trials investigating Psidium cattleianum or Bupubili for any health outcome, including gastritis, have been identified in the published literature. Available data derive exclusively from in vitro enzyme inhibition assays, MCF-7 breast cancer cell line experiments, and antioxidant capacity measurements, none of which constitute clinical evidence for efficacy or safety in humans. Effect sizes from in vitro studies (e.g., 90.37% collagenase inhibition, 5-LOX IC50 2.38 μL/mL) are pharmacologically interesting but cannot be extrapolated to therapeutic doses or outcomes without bioavailability and pharmacokinetic bridging studies. Confidence in clinical benefit is therefore very low; the traditional use in gastritis among the Mampa people represents the primary real-world use signal and warrants formal ethnopharmacological investigation and subsequent clinical evaluation.

Nutritional Profile

Red Psidium cattleianum fruits contain fructose up to 22.83 g/100 g dry matter (DM) and glucose up to 16.42 g/100 g DM as primary carbohydrates, with citric acid as the dominant organic acid at up to 135.35 mg/g DM. Carotenoid content is notable, with β-cryptoxanthin comprising 44.8% of total carotenoids, and cyanidin 3-glycoside serving as the principal anthocyanin pigment; concentrations vary with ripening stage and geographic growing location. Leaf dry extracts are exceptionally rich in total phenolics (449.38 mg GAE/g DE), phenolic acids (21.04 mg CAE/g DE), and flavonoids (1.51 mg QE/g DE), with gallic acid (m/z 169) and ellagic acid as the dominant identified compounds by LC-MS. Bioavailability of these polyphenols has not been studied for this species specifically; general polyphenol absorption factors such as food matrix interactions, gut microbiome biotransformation of ellagitannins to urolithins, and first-pass metabolism would be expected to modulate systemic availability.

Preparation & Dosage

- **Dry Leaf Extract (Research Form)**: Used in vitro at concentrations yielding TPC of 449.38 mg GAE/g DE; no human dose established. Traditional preparation likely involves aqueous decoction of dried leaves.
- **Aqueous Leaf Decoction (Traditional)**: Leaves are boiled in water and the resulting tea consumed orally for gastritis in Mampa traditional medicine; no standardized volume, frequency, or duration has been documented in the scientific literature.
- **Leaf Essential Oil (Experimental)**: Obtained by hydrodistillation or supercritical CO2 extraction (yield up to 0.62%); used in cell-based assays at IC50 values of 2.38–5.32 μg/mL or μL/mL. No human-applicable dose has been established.
- **Flower Essential Oil (Experimental)**: Obtained by hydrodistillation (yield up to 1.4%); COX-2 inhibition IC50 of 2.575 μL/mL in vitro. Not formulated for human supplementation.
- **Fruit Pulp Beverage**: Fruit-based beverages contain TPC of 150–184 mg GAE/100 mL; consumed as food without therapeutic dosing specifications.
- **Standardization Note**: No commercial standardized extract exists; no pharmacopoeial monograph or regulatory-approved dosage form has been established for Bupubili or Psidium cattleianum.

Synergy & Pairings

The combination of ellagitannins from Psidium cattleianum with vitamin C (ascorbic acid) may enhance antioxidant capacity through regeneration of phenoxyl radicals and additive radical scavenging, a synergy well-documented for polyphenol-ascorbate pairs in gastric mucosal protection models. Pairing β-caryophyllene-rich Bupubili essential oil with other CB2 receptor-active terpenes such as those in copaiba (Copaifera officinalis) resin could theoretically produce additive anti-inflammatory effects through convergent endocannabinoid and eicosanoid pathway modulation, though this specific combination has not been studied. Quercetin, already present endogenously in Bupubili leaf extracts, is known to enhance the pro-apoptotic activity of compounds acting on the Bax/Bcl-2 axis, suggesting that quercetin-standardized co-extracts could amplify the observed anticancer activity in future preclinical models.

Safety & Interactions

No formal human safety studies, toxicology trials, or adverse event reports have been published for Psidium cattleianum consumed as a therapeutic extract or Bupubili preparation; in vitro data reveal no overt cytotoxicity to normal cell lines at the concentrations tested, but this does not constitute a safety clearance for human use. The high tannin and ellagitannin content in leaf extracts raises theoretical concerns regarding gastrointestinal irritation, reduced mineral absorption (particularly iron and zinc via chelation), and potential hepatotoxic effects at high doses, consistent with risks associated with high-tannin plant extracts as a class. No drug-drug interactions have been empirically studied; however, the demonstrated COX-2 and 5-LOX inhibitory activity suggests a theoretical pharmacodynamic interaction with NSAIDs or corticosteroids that could potentiate anti-inflammatory or anticoagulant effects. Guidance for pregnant or lactating individuals cannot be provided in the absence of any reproductive toxicology data, and use during these periods should be avoided until safety is established.